Design Therapeutics, Inc. DSGN Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Design Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Design Therapeutics, Inc.'s financing cash flow?
- Design Therapeutics, Inc. (DSGN) reported financing cash flow of $19.93M in Q1 2026.
- How has Design Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Design Therapeutics, Inc.'s financing cash flow increased by 86569.6% year-over-year, from $23K to $19.93M.
- What is the long-term trend for Design Therapeutics, Inc.'s financing cash flow?
- Over 3 years (2021 to 2025), Design Therapeutics, Inc.'s financing cash flow has grown at a -59.2% compound annual growth rate (CAGR), from $379.21M to $25.74M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.